Working to Eradicate Gynecologic Cancers

Beth Y. Karlan, MD

Director, Women's Cancer Program
Cedars-Sinai Medical Center
Samuel Oschin Comprehensive Cancer Institute
8700 Beverly Blvd., Suite 290W
Los Angeles, CA
USA 90048


Biographical Sketch: As a physician and translational researcher, Dr. Beth Y. Karlan has more than 20 years experience in gynecologic oncology and an extensive background scientific publication. She is Editor-In-Chief of both the journal Gynecologic Oncology and the journal Gynecologic Oncology Case Reports. She has authored more than 200 publications and edited thousands submitted by colleagues and those she has mentored. Dr. Karlan’s research submissions have been granted funding from The NIH, NCI, DOD and American Cancer Society and many private and public foundations. She is widely recognized as a leading expert in the field of gynecologic oncology and her efforts have helped shape the current standards of care for the specialty."

Papers:
101 -Featured Poster Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer 130 - Featured Poster Too much, too late: aggressive measures and the timing of end-of life care discussions in women with gynecologic malignancies 194 - Poster Session A A KRAS hot spot mutation correlates with MLH1 methylation in endometrial carcinomas with microsatellite instability: a potential triage tool for Lynch syndrome evaluation 330 - Poster Session A Lack of genomic predictors of recurrence in uterine carcinoma 331 - Poster Session A Genomic characterization of grade 3 endometrial carcinoma 353 - Poster Session B A novel clinical trial recruitment strategy for women's cancers 361 - Poster Session B Breast cancer following ovarian cancer in BRCA mutation carriers: what is the cost of surveillance? 368 - Poster Session B Risk of breast cancer following ovarian cancer and the impact on overall survival 424 - Poster Session B Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer 487 - Poster Session B Risk factors for recurrent high grade vaginal intraepithelial neoplasia and progression to carcinoma Lecturette Debate: Neoadjuvant Chemotherapy (Con)